Compliance and enforcement
We monitor and enforce compliance with laws that regulate health products.
How we manage compliance
We take a risk-based, evidence-drive approach that puts public safety first. Under the Therapeutic Goods Act 1989, we work to protect Australians by educating industry, assessing risks and taking action when needed.
Watch our video to learn more or explore our regulatory compliance framework.
Report a breach
We want to hear about:
- breaches of the Therapeutic Goods Act
- counterfeit products
- questionable practices
- non-compliant advertising related to therapeutic goods.
Know our compliance principles
We have re-aligned our approach to determining compliance priorities for 2026 and 2027. The new approach sees our priorities structured around five compliance principles, each supported by routinely reviewed priority focus areas. These principles guide how we address illegal import, export, manufacture, supply and advertising of therapeutic goods.
The five principles are:
- Safeguarding therapeutic goods
- Educate to empower
- Protect those most at risk
- Leverage digital capability
- Strengthen enforcement.
Learn more about our compliance principles
Find a compliance outcome
When we receive a report of a breach, we investigate and take action based on the level of risk to public health and safety. Our actions range from education and warnings to fines and legal action.
Understand the ways we respond to breaches of therapeutic good regulations and find the latest outcomes.
Page history
'Know our compliance principles' section updated.
Original publication.
'Know our compliance principles' section updated.
Original publication.
Latest alerts
-
We are advising consumers that ‘Pharmatech’ branded MK-677 capsules (containing ibutamoren) may pose a serious risk to your health and should not be taken.
-
We are advising consumers that Artri Ajo King tablets may pose a serious risk to your health and should not be taken.
-
TGA continues to see imports of counterfeit Botox vials despite a previous warning issued in July 2025.
Latest articles
-
TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response
We have expanded our priority focus areas to include unapproved peptide products, following increased detection of unlawful importation, supply and advertising, posing potential risks to consumer safety. -
Individual issued 27 infringement notices for allegedly supplying Melanotan II
We have issued 27 infringement notices, totalling $101,412, to a NSW-based individual for the alleged unlawful supply of Melanotan II to Australian consumers in contravention of the Therapeutic Goods Act 1989. -
Unlawful therapeutic goods seized in global operation
We have led Australia's participation in INTERPOL's Operation Pangea XVIII, a coordinated global action targeting the illegal trade of illicit and counterfeit therapeutic goods.
Latest publications
-
This report summarises the outcomes of the Pharmacovigilance Inspection Program in the 2-year period. The deficiencies identified are presented along with case studies of critical deficiencies from this reporting period, to support medicine sponsors in the continual improvement of their pharmacovigilance systems.
-
The report cards show the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.
-
Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).